


OPDIVO® (nivolumab)

Patient Alert Card

▼ Nivolumab is subject to additional monitoring to quickly identify new safety information. You can help by reporting any side effects that you may get to your Doctor

© 2017 Bristol-Myers Squibb Company. All rights reserved. - V9.1EU/28APR2017

 Bristol-Myers Squibb



OPDIVO® (nivolumab)

This card contains important information.

Always carry this card with you and show it if you need to consult another doctor (for example if you are travelling).

Tell your doctor right away if you have any of these symptoms or any other symptoms

LUNGS¹

breathing difficulties, cough.

BOWEL and STOMACH¹

diarrhoea (watery, loose or soft stools), blood or mucous in your stools, dark-coloured stools, pain or tenderness in your stomach or abdominal area.

LIVER¹

eye or skin yellowing (jaundice), pain on the right side of your stomach area, tiredness.

KIDNEYS¹

decreased amount of urine.

DIABETES/DIABETIC KETOACIDOSIS¹

thirst, increased appetite with loss of weight, tiredness, weakness, drowsiness, depression, irritability, feeling unwell, increased amount of urine.

SKIN¹

severe skin reactions, like skin rash with or without itching, blisters and/or peeling of the skin (possibly fatal), ulcers, dry skin, skin nodules.

HORMONE-PRODUCING GLANDS¹

headaches, blurry or double vision, fatigue, tiredness, weight changes, behavioural changes (eg less sex drive, irritability or forgetfulness).

MUSCLES (including heart)¹

signs and symptoms of myositis (inflammation of the muscles), myocarditis (inflammation of the heart muscle), and rhabdomyolysis (breakdown of skeletal muscle), which may include muscle pain, stiffness, weakness, chest pain, irregular heartbeat, palpitations, confusion, decreased amount of urine, dark urine, or severe fatigue.

OTHER¹

eye pain or redness, blurry vision, or other vision problems; upper abdominal pain (inflammation of the pancreas), decreased appetite, nausea or vomiting, indigestion or heartburn, tingling or numbness in arms and legs or difficulty walking; fever, swollen lymph nodes; signs or symptoms of inflammation of the brain, which may include headache, fever, seizures, stiff neck, tiredness, confusion, weakness or drowsiness

IMPORTANT

- Early management of side effects reduces the likelihood that treatment with nivolumab or nivolumab in combination with ipilimumab will need to be temporarily or permanently stopped, allowing patients to get the maximum benefit from treatment.
- Symptoms that may appear mild can quickly worsen if left untreated.¹
- Don't try to treat these symptoms yourself.
- Report any of these symptoms or any other symptoms to your doctor right away.
- Signs and symptoms may be delayed and may occur weeks to months after your last injection.¹
- Carry this Patient Alert Card, show it to any doctor you might interact with, and say that you are being treated with nivolumab or nivolumab in combination with ipilimumab.

TELL YOUR DOCTOR IMMEDIATELY IF YOU:

- know you are allergic to nivolumab or any other medicine or medicine ingredients.
- have an autoimmune disease.
- have melanoma of the eye.
- if you have experienced side effects with another drug, such as ipilimumab.
- have been told cancer has spread to your brain.
- have taken medicine to suppress your immune system. Nivolumab may cause solid organ transplant rejection
- have history of inflammation of lungs.
- are pregnant or planning to become pregnant, or are breast feeding.
- are taking or have taken any other medicines.
- are on a low salt diet.

More information on OPDIVO® Package Leaflet or call Medical Information at 00 356 2397 6505

My Doctor's contact information

Name of Doctor

.....
.....

Office Phone

.....
.....

After-hours Phone

.....
.....

My contact information

My Name and Phone Number

.....
.....

Emergency Contact (in case of emergency)

.....
.....

IMPORTANT Information For Healthcare Providers

- This patient is treated with **nivolumab** or **nivolumab in combination with ipilimumab**.
- Immune-related adverse reactions (irARs), may appear at any time during the treatment or months after its discontinuation.
- Early diagnosis and appropriate management are essential to minimise life-threatening complications. Nivolumab specific management guidelines for irARs are available.
- If you are a doctor who is not a specialist in oncology, please contact an oncologist

Please consult OPDIVO® Summary of Product Characteristics or call Medical Information at 00 356 2397 6505 for more information.

1. OPDIVO™ Package Leaflet.

© 2017 Bristol-Myers Squibb Company. All rights reserved. - V9.1EU/28APR2017

1506MT17NP02811-01
APPROVAL DATE: JUNE 2017